These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33259637)

  • 1. Adjuvant therapy following induction therapy and surgery improves survival in N2-positive non-small cell lung cancer.
    White AA; Lee DN; Mazzola E; Kucukak S; Polhemus E; Jaklitsch MT; Mentzer SJ; Wee JO; Bueno R; Swanson SJ
    J Surg Oncol; 2021 Feb; 123(2):579-586. PubMed ID: 33259637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.
    Spaggiari L; Casiraghi M; Guarize J; Brambilla D; Petrella F; Maisonneuve P; De Marinis F
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):593-602. PubMed ID: 28043483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors in neoadjuvant treatment followed by surgery in stage IIIA-N2 non-small cell lung cancer: a multi-institutional study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).
    Couñago F; Montemuiño S; Martin M; Taboada B; Calvo-Crespo P; Samper-Ots MP; Alcántara P; Corona J; López-Guerra JL; Murcia-Mejía M; López-Mata M; Jové-Teixidó J; Chust M; Díaz-Díaz V; de Ingunza-Barón L; García-Cañibano T; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Puertas MM; Thuissard IJ; Sanz-Rosa D; de Dios NR
    Clin Transl Oncol; 2019 Jun; 21(6):735-744. PubMed ID: 30430394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.
    Jeannin G; Merle P; Janicot H; Thibonnier L; Kwiatkowski F; Naame A; Chadeyras JB; Galvaing G; Belliere A; Filaire M; Verrelle P
    Chin Clin Oncol; 2015 Dec; 4(4):39. PubMed ID: 26730751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America.
    Veeramachaneni NK; Feins RH; Stephenson BJ; Edwards LJ; Fernandez FG
    Ann Thorac Surg; 2012 Sep; 94(3):922-6; discussion 926-8. PubMed ID: 22742842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mediastinal downstaging after induction treatment is not a significant prognostic factor to select patients who would benefit from surgery: the clinical value of the lymph node ratio.
    Renaud S; Falcoz PE; Olland A; Reeb J; Santelmo N; Massard G
    Interact Cardiovasc Thorac Surg; 2015 Feb; 20(2):222-7. PubMed ID: 25413781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy followed by surgery in lung cancer: Indian scenario.
    Kumar S; Saikia J; Kumar V; Malik PS; Madan K; Jain D; Bharati S
    Curr Probl Cancer; 2020 Jun; 44(3):100563. PubMed ID: 32265058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy.
    Amini A; Correa AM; Komaki R; Chang JY; Tsao AS; Roth JA; Swisher SG; Rice DC; Vaporciyan AA; Lin SH
    Ann Thorac Surg; 2012 Sep; 94(3):914-20. PubMed ID: 22819472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperfractionated irradiation with 3 cycles of induction chemotherapy in stage IIIA-N2 lung cancer.
    Chen F; Okubo K; Sonobe M; Shibuya K; Matsuo Y; Kim YH; Yanagihara K; Bando T; Date H
    World J Surg; 2012 Dec; 36(12):2858-64. PubMed ID: 22926283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients.
    Rajaram R; Correa AM; Xu T; Nguyen QN; Antonoff MB; Rice D; Mehran R; Roth J; Walsh G; Swisher S; Hofstetter WL; Vaporciyan A; Cascone T; Tsao AS; Papadimitrakopoulou VA; Gandhi S; Liao Z; Sepesi B
    Clin Lung Cancer; 2020 Jul; 21(4):e294-e301. PubMed ID: 32089476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival.
    Bueno R; Richards WG; Swanson SJ; Jaklitsch MT; Lukanich JM; Mentzer SJ; Sugarbaker DJ
    Ann Thorac Surg; 2000 Dec; 70(6):1826-31. PubMed ID: 11156079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer.
    Yang CF; Adil SM; Anderson KL; Meyerhoff RR; Turley RS; Hartwig MG; Harpole DH; Tong BC; Onaitis MW; D'Amico TA; Berry MF
    Eur J Cardiothorac Surg; 2016 Jun; 49(6):1607-13. PubMed ID: 26719403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease.
    Kim HK; Cho JH; Choi YS; Zo JI; Shim YM; Park K; Ahn MJ; Ahn YC; Kim K; Kim J
    Lung Cancer; 2016 Jun; 96():56-62. PubMed ID: 27133751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis.
    Toyooka S; Kiura K; Shien K; Katsui K; Hotta K; Kanazawa S; Date H; Miyoshi S
    Interact Cardiovasc Thorac Surg; 2012 Dec; 15(6):954-60. PubMed ID: 22976995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
    Shinde A; Horne ZD; Li R; Glaser S; Massarelli E; Koczywas M; Erhunmwunsee L; Reckamp KL; Weksler B; Salgia R; Beriwal S; Amini A
    Lung Cancer; 2019 Jul; 133():136-143. PubMed ID: 31200820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
    Xu YP; Li B; Xu XL; Mao WM
    Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer.
    Sawabata N; Keller SM; Matsumura A; Kawashima O; Hirono T; Osaka Y; Maeda H; Fukai S; Kawahara M;
    Lung Cancer; 2003 Oct; 42(1):69-77. PubMed ID: 14512190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.
    Marulli G; Verderi E; Zuin A; Schiavon M; Battistella L; Perissinotto E; Romanello P; Favaretto AG; Pasello G; Rea F
    Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):256-62; discussion 262. PubMed ID: 24824495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodality Therapy for N2 Non-Small Cell Lung Cancer: An Evolving Paradigm.
    Spicer JD; Shewale JB; Nelson DB; Mitchell KG; Bott MJ; Vallières E; Wilshire CL; Vaporciyan AA; Swisher SG; Jones DR; Darling GE; Sepesi B
    Ann Thorac Surg; 2019 Jan; 107(1):277-284. PubMed ID: 30227129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.